SynBioBeta Speaker
Per Falholt
21st.BIO
CSO, Co-founder
Per Falholt is a Danish chemical engineer with more than 40 years of experience in industrial biotechnology and innovation. He spent over three decades at Novo Nordisk and Novozymes, where he held senior leadership roles, including EVP of R&D, and was responsible for global research centers and the successful launch of around 200 new enzyme products across multiple industries.
Since 2016, he has co-founded several biotech companies, including Bactolife, Lactobio (sold to L’Oréal in 2023), ExelCyte, and 21st.BIO, where he serves as co-founder of a fast-growing Danish-American biotech firm. He is also an inventor on ~15 patents and contributed to pioneering enzyme technologies, large-scale protein production, and the application of CRISPR and other advanced biotech tools.
Falholt has served as Chairman of DTU’s Board (2012–2020) and currently holds board positions at Danfoss, Co-Ro, and several biotech ventures, as well as advisory roles at DTU and international life science companies.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Per
This Year
•
-
Biomanufacturing
The Road to Commercial Scale: Capital and Market Demands Beyond the Pilot Plant
Scaling bio-based products to commercial production requires balancing technical readiness with market and financial realities. This session examines the capital investments, regulatory planning, and supply chain strategies necessary to move beyond the pilot stage. Experts will share lessons on aligning production capacity with demand forecasts, managing operational risk, and structuring partnerships that unlock funding and market access. Attendees will gain practical insights into navigating investor expectations, scaling efficiently without compromising quality, and making strategic decisions that ensure products can succeed commercially while meeting evolving market needs and sustainability goals.
Get a Ticket
Featuring
Cindy Groff-Vindman
CINBIO
Founder
Per Falholt
21st.BIO
CSO, Co-founder
Launched ~200 enzyme products, industrial biotech scale-up expert
Vanderlei Bellettini
ADM
VP Precision Ferm. Ops
Bioprocess scale-up veteran turning fermentation into real-world products
Richard Kenny
Hawkwood Bio
Founder & Mng. Partner
Techno-economic analysis for the bioeconomy
Verena Kallhoff
GHP
Sr. Dir, Global Life Sciences
Riccardo LoCascio
Novonesis
Partnering - Precision Proteins
•
-
Biomanufacturing
The Road to Commercial Scale: Capital and Market Demands Beyond the Pilot Plant
Scaling bio-based products to commercial production requires balancing technical readiness with market and financial realities. This session examines the capital investments, regulatory planning, and supply chain strategies necessary to move beyond the pilot stage. Experts will share lessons on aligning production capacity with demand forecasts, managing operational risk, and structuring partnerships that unlock funding and market access. Attendees will gain practical insights into navigating investor expectations, scaling efficiently without compromising quality, and making strategic decisions that ensure products can succeed commercially while meeting evolving market needs and sustainability goals.
Get a Ticket
Featuring
Cindy Groff-Vindman
CINBIO
Founder
Per Falholt
21st.BIO
CSO, Co-founder
Launched ~200 enzyme products, industrial biotech scale-up expert
Vanderlei Bellettini
ADM
VP Precision Ferm. Ops
Bioprocess scale-up veteran turning fermentation into real-world products
Richard Kenny
Hawkwood Bio
Founder & Mng. Partner
Techno-economic analysis for the bioeconomy
Verena Kallhoff
GHP
Sr. Dir, Global Life Sciences
Riccardo LoCascio
Novonesis
Partnering - Precision Proteins
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
